MYRICX PHARMA
Myricx Pharma is a small molecule drug discovery company engaged in developing novel proprietary inhibitors of human N-myristoyltransferases (NMT), with a primary focus in oncology but also exploring potential applications across other diseases.
MYRICX PHARMA
Social Links:
Industry:
Biotechnology Life Science
Founded:
2019-01-01
Address:
Stevenage, Herefordshire, United Kingdom
Country:
United Kingdom
Website Url:
http://www.myricxpharma.com
Total Employee:
1+
Status:
Active
Total Funding:
4.5 M GBP
Technology used in webpage:
Euro Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS
Similar Organizations
Axcella
Axcella is a biotechnology company that treats diseases using endogenous metabolic modulators.
Enliven Therapeutics
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.
MS2 Array
MS2 Array operator is a drug discovery company intending to discover small molecule inhibitors of RNA.
NMD Pharma
NMD Pharma is a small molecule drug discovery company that develops novel treatments of neuromuscular disorders.
Syros Pharmaceuticals
Syros Pharmaceuticals is a life sciences company that focuses on treating diseases by mapping gene regulatory circuits.
Voyager Therapeutics
Voyager Therapeutics is a biotechnology company specializing in gene therapy and neurology.
XinThera
XinThera is a drug discovery company focused on building small molecule oncology and immunology pipeline.
Current Employees Featured
Founder
Investors List
Sofinnova Partners
Sofinnova Partners investment in Seed Round - Myricx Pharma
Brandon Capital Partners
Brandon Capital Partners investment in Seed Round - Myricx Pharma
Key Employee Changes
| Date | New article |
|---|---|
| 2022-02-22 | Myricx Pharma Announces Senior Team Expansion with Appointment of CMO, and Heads of Biology and Bioinformatics |
Official Site Inspections
http://www.myricxpharma.com
- Host name: cpweb6-premium.active-ns.com
- IP address: 84.18.203.45
- Location: United Kingdom
- Latitude: 51.4964
- Longitude: -0.1224
- Timezone: Europe/London
More informations about "Myricx Pharma"
Myricx Bio – Developing the first class of ADCs based on NMT …
Sep 12, 2024 · We are a biotech company, headquartered in London, focused on discovering and developing a completely novel class of payloads for antibody drug conjugates (ADCs), based …See details»
About Us – Myricx Bio
A private company, Myricx is backed by a strong syndicate of experienced life science and healthcare investors including Abingworth, Brandon Capital, British Patient Capital, Cancer Research Horizons, Eli Lilly and Company, Novo …See details»
Myricx Bio - Crunchbase Company Profile & Funding
Myricx Bio is a biotechnology company that develops novel NMT inhibitor payloads for ADCs to treat cancer. Myricx Bio secured $114 million in a Series A funding round to advance its ADCs into clinical development. This funding …See details»
Myricx Pharma - VentureRadar
Website: https://myricxpharma.com Develops novel proprietary inhibitors of human N-myristoyltransferases (NMT) for targeted cancer therapies, focusing on oncology and exploring …See details»
Myricx Pharma Presents Positive Pre-clinical PoC Data at AACR for its
Apr 17, 2023 · Myricx Pharma Ltd (“Myricx”) is a small molecule drug discovery company engaged in developing novel proprietary inhibitors of human N -myristoyltransferases (NMT) …See details»
Myricx Pharma - Craft
See insights on Myricx Pharma including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
Myricx Pharma – Brandon BioCatalyst
Myricx Pharma (“Myricx”) is a small molecule drug discovery company engaged in developing novel proprietary inhibitors of human N-myristoyltransferases (NMT), with a primary focus in …See details»
Myricx Bio — Sofinnova Partners
Myricx Bio formerly Myricx Pharma is a drug discovery company focused on developing small molecule inhibitors that selectively target the human N-myristoyltransferases (NMT) in cancer. …See details»
Myricx Pharma Announces Senior Team Expansion With …
Stevenage, UK, February 22 2022 – Myricx Pharma (‘Myricx’), a drug discovery company focused on developing small molecule inhibitors that selectively target the human N …See details»
Myricx Pharma Company Information - Funding, Investors, and More
Jan 1, 2020 · Myricx Pharma, based in London, operates a drug discovery platform specializing in small molecule inhibitors for specific diseases. By focusing on targeted treatments, Myricx has …See details»
Myricx Pharma - Company info. interviews, news
Apr 20, 2023 · Myricx Pharma, an oncology drug discovery company specializing in precision medicines based on its N-myristoyltransferase (NMT) platform, has recently presented positive …See details»
Myricx Pharma Launches With £4.5M Financing To Progress Its …
Stevenage, UK, November 16, 2020 – Myricx Pharma (‘Myricx’), a drug discovery company focused on developing small molecule inhibitors that selectively target the human N …See details»
Myricx Pharma Announces Board and Executive Appointments
Apr 20, 2021 · Myricx Pharma Ltd (“Myricx”) is a small molecule drug discovery company engaged in developing novel proprietary inhibitors of human N -myristoyltransferases (NMT), …See details»
Myricx Pharma Announces Senior Team Expansion with ... - BioSpace
Myricx Pharma Ltd (“Myricx”) is a small molecule drug discovery company engaged in developing novel proprietary inhibitors of human N-myristoyltransferases (NMT), with a primary focus in …See details»
Myricx Pharma Announces Senior Team Expansion with …
Feb 22, 2022 · Myricx Pharma Ltd (“Myricx”) is a small molecule drug discovery company engaged in developing novel proprietary inhibitors of human N -myristoyltransferases (NMT), …See details»
Myricx Pharma Launches with £4.5M Financing to ... - Business Wire
Nov 16, 2020 · Myricx Pharma Ltd (“Myricx”) is a small molecule drug discovery company engaged in developing novel proprietary inhibitors of human N -myristoyltransferases (NMT), …See details»
Myricx Bio signs licence deal for WuXi Biologics’ antibody
Nov 22, 2023 · UK-based biotech company Myricx Bio has signed a licence agreement for contract research, development and manufacturing organisation (CRDMO) WuXi Biologics’s …See details»
MYX-2449 Drug Profile - Ozmosi
Apr 17, 2023 · (Sourced from: https://myricxpharma.com/science/our-programmes/) Myricx’s most advanced ADC, MYX2499, comprises a specific selective and ultrapotent NMTi payload …See details»
Pipeline – Myricx Bio
We are progressing a pipeline of proprietary differentiated ADCs based on our novel N -myristoyltransferase inhibitor (NMTi) payload chemistry platform to address serious unmet …See details»
Biocytogen and Myricx Bio partner for development of ADCs
Sep 8, 2023 · Myricx will provide its linker and payload and Biocytogen will conjugate them with its RenMice-derived fully human antibodies to create ADCs. Biocytogen will conduct feasibility …See details»